1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Orion Pushing Ahead In Prostate Cancer, R&D Reorganized

Extending Nubeqa's Indications

 
• By John Davis

Finland’s Orion Corporation is highlighting its prostate cancer and other oncology candidates in its reorganized R&D.

Espoo, Finland
Espoo, Finland, Where Orion Corp Is Headquartered • Source: Shutterstock

Finland’s mid-sized pharmaceutical company, Orion Corporation, which develops and markets across branded products, generics and APIs, is evaluating two more potential prostate cancer therapies, ODM-208, and ODM-209, and is joining collaborator Bayer AG on the evaluation of the marketed product, Nubeqa (darolutamide), in a broader range of prostate cancer patients. 

ODM-208 and ODM-209 are selective hormone synthesis inhibitors, or CYP11A1 inhibitors, and are first-in-class candidates, the company noted during its 2020 annual results presentation on 9 February

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.